Experiments in model systems have shown that FGFR-specific inhibitors may be valuable in treating multiple myeloma, bladder and endometrial cancers. FGF1, FGF2 and FGF4 have been studied in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback